UPDATE: Credit Suisse Downgrades The Medicines Company Following Negative Cangrelor Panel

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on The Medicines Company (NASDAQ: MDCO ) from Outperform to Neutral, and lowered the price target from $45.00 to $35.00. In the report, Credit Suisse noted, “The 7 to 2 vote against approval of cangrelor was an